<?xml version='1.0' encoding='utf-8'?>
<document id="30912163"><sentence text="Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers."><entity charOffset="23-34" id="DDI-PubMed.30912163.s1.e0" text="ciclosporin" /><entity charOffset="87-98" id="DDI-PubMed.30912163.s1.e1" text="fluconazole" /><entity charOffset="144-155" id="DDI-PubMed.30912163.s1.e2" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.30912163.s1.e0" e2="DDI-PubMed.30912163.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30912163.s1.e0" e2="DDI-PubMed.30912163.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30912163.s1.e0" e2="DDI-PubMed.30912163.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30912163.s1.e1" e2="DDI-PubMed.30912163.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30912163.s1.e1" e2="DDI-PubMed.30912163.s1.e2" /></sentence><sentence text="Rivaroxaban exposure is considerably increased by drugs that are combined P-glycoprotein (P-gp) and strong cytochrome P450 (CYP) 3A inhibitors (e"><entity charOffset="0-11" id="DDI-PubMed.30912163.s2.e0" text="Rivaroxaban" /></sentence><sentence text="g" /><sentence text=" ketoconazole)"><entity charOffset="1-13" id="DDI-PubMed.30912163.s4.e0" text="ketoconazole" /></sentence><sentence text=" The aim of the present study was to investigate the effects of the potent P-gp inhibitor ciclosporin and its combination with the moderate CYP3A inhibitor fluconazole on rivaroxaban pharmacokinetics and on CYP3A activity"><entity charOffset="156-167" id="DDI-PubMed.30912163.s5.e0" text="fluconazole" /><entity charOffset="171-182" id="DDI-PubMed.30912163.s5.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.30912163.s5.e0" e2="DDI-PubMed.30912163.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30912163.s5.e0" e2="DDI-PubMed.30912163.s5.e1" /></sentence><sentence text="" /><sentence text="Twelve healthy volunteers received 20 mg rivaroxaban orally alone, in combination with ciclosporin (dose-individualized oral regimen), and in combination with ciclosporin and fluconazole (400 mg day-1 orally)"><entity charOffset="41-52" id="DDI-PubMed.30912163.s7.e0" text="rivaroxaban" /><entity charOffset="87-98" id="DDI-PubMed.30912163.s7.e1" text="ciclosporin" /><entity charOffset="159-170" id="DDI-PubMed.30912163.s7.e2" text="ciclosporin" /><entity charOffset="175-186" id="DDI-PubMed.30912163.s7.e3" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.30912163.s7.e0" e2="DDI-PubMed.30912163.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30912163.s7.e0" e2="DDI-PubMed.30912163.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30912163.s7.e0" e2="DDI-PubMed.30912163.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30912163.s7.e0" e2="DDI-PubMed.30912163.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30912163.s7.e1" e2="DDI-PubMed.30912163.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30912163.s7.e1" e2="DDI-PubMed.30912163.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30912163.s7.e1" e2="DDI-PubMed.30912163.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30912163.s7.e2" e2="DDI-PubMed.30912163.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30912163.s7.e2" e2="DDI-PubMed.30912163.s7.e3" /></sentence><sentence text=" CYP3A4 activity was estimated using a midazolam microdose" /><sentence text=" Pharmacokinetics was analysed using noncompartmental and compartmental methods" /><sentence text="" /><sentence text="Compared to baseline, ciclosporin increased rivaroxaban average exposure by 47% (90% confidence interval 28-68%), maximum concentration by 104% (70-146%), and decreased CYP3A4 activity by 34% (25-42%)"><entity charOffset="22-33" id="DDI-PubMed.30912163.s11.e0" text="ciclosporin" /><entity charOffset="44-55" id="DDI-PubMed.30912163.s11.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.30912163.s11.e0" e2="DDI-PubMed.30912163.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30912163.s11.e0" e2="DDI-PubMed.30912163.s11.e1" /></sentence><sentence text=" Ciclosporin combined with fluconazole increased rivaroxaban average exposure by 86% (58-119%) and maximum concentration by 115% (83-153%), which was considerably stronger than observed in historical controls receiving rivaroxaban with fluconazole alone, and decreased CYP3A4 activity by 79% (76-82%)"><entity charOffset="1-12" id="DDI-PubMed.30912163.s12.e0" text="Ciclosporin" /><entity charOffset="27-38" id="DDI-PubMed.30912163.s12.e1" text="fluconazole" /><entity charOffset="49-60" id="DDI-PubMed.30912163.s12.e2" text="rivaroxaban" /><entity charOffset="219-230" id="DDI-PubMed.30912163.s12.e3" text="rivaroxaban" /><entity charOffset="236-247" id="DDI-PubMed.30912163.s12.e4" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e0" e2="DDI-PubMed.30912163.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e0" e2="DDI-PubMed.30912163.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e0" e2="DDI-PubMed.30912163.s12.e2" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e0" e2="DDI-PubMed.30912163.s12.e3" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e0" e2="DDI-PubMed.30912163.s12.e4" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e1" e2="DDI-PubMed.30912163.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e1" e2="DDI-PubMed.30912163.s12.e2" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e1" e2="DDI-PubMed.30912163.s12.e3" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e1" e2="DDI-PubMed.30912163.s12.e4" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e2" e2="DDI-PubMed.30912163.s12.e2" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e2" e2="DDI-PubMed.30912163.s12.e3" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e2" e2="DDI-PubMed.30912163.s12.e4" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e3" e2="DDI-PubMed.30912163.s12.e3" /><pair ddi="false" e1="DDI-PubMed.30912163.s12.e3" e2="DDI-PubMed.30912163.s12.e4" /></sentence><sentence text="" /><sentence text="Patients treated with rivaroxaban in combination with single modulators of multiple elimination pathways or multiple modulators of single elimination pathways (CYP3A, P-gp) require particular care"><entity charOffset="22-33" id="DDI-PubMed.30912163.s14.e0" text="rivaroxaban" /></sentence><sentence text="" /></document>